



IFW

THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8

In re Application of: :
DRUMM, et al. : Confirmation No. 9864
Serial No. 10/511,657 : Group Art Unit: 1635
Filed: April 18, 2005 : Examiner: Wollenberger, Louis V.

For: MEANS AND METHODS FOR THE SPECIFIC MODULATION OF
TARGET GENES IN THE CNS AND THE EYE AND METHODS FOR
THEIR IDENTIFICATION

Date Mailed: May 31, 2007

I HEREBY CERTIFY THAT THIS SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE
VIA FIRST CLASS MAIL UNDER 37 CFR 1.8 AND IS ADDRESSED TO MAIL STOP
AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA
22313-1450

Kathleen Pujol

(Typed or printed name of person mailing paper or fee)

(Signature of person mailing paper or fee)

Documents Mailed:
Information Disclosure Statement (2 pages)
Form PTO-1449 (2 pages)
References Cited (35)
Certificate of Mailing
Postcard

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

DRUMM, et al.

Serial No. 10/511,657

Filed: April 18, 2005



: Confirmation No. 9864

: Group Art Unit: 1635

: Examiner: Wollenberger, Louis V.

For: MEANS AND METHODS FOR THE SPECIFIC MODULATION OF
TARGET GENES IN THE CNS AND THE EYE AND METHODS FOR
THEIR IDENTIFICATION

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. It is respectfully requested that the documents be expressly considered and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

The undersigned asserts that each item of information contained in the information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.



PATENT

AUTHORIZATION

No fee is required. The Commissioner is hereby authorized to charge any additional fees which may be required for this submission, or credit any overpayment to Deposit Account No. 50-0436.

Respectfully submitted,

PEPPER HAMILTON LLP

Raymond A. Miller
Registration No. 42,891

Pepper Hamilton LLP
500 Grant Street, 50th Floor
Pittsburgh, PA 15219
Telephone: (412) 454-5000
Facsimile: (412) 281-0717
Date: May 31, 2007



Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/511,657
Filing Date	April 18, 2005
First Named Inventor	Drumm
Group Art Unit	1635
Examiner Name	Wollenberger, Louis V.
Attorney Docket Number	129402.00201

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
/L.W./	A1	2002/0054902	A1	Pardridge	05-09-2002	
	A2	5,550,289	A	Eppstein et al.	08-27-1996	

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
	B1	WO	98/48009	A2	University of Florida	10-29-1998		
	B2	WO	94/08026	A1	Rhone-Poulenc Rorer S.A.	04-14-1994		
	B3	WO	02/11666	A2	D-Pharm Ltd.	02-14-2002		
	B4	WO	99/12572	A1	University of Florida	03-18-1999		
	B5	EP	1229134	A2	Necleonic, Inc. et al.	08-07-2002		
	B6	WO	01/83729	A	Novartis AG	11-08-2001		
	B7	WO	01/36646	A	Cancer Res. Campaign Tech Lim	05-25-2001		
	B8	WO	00/44914	A	Medical College of Georgia Research Institute	08-03-2000		
	B9	WO	02/088320	A	University of Florida	11-07-2002		

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner's Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or county where published.	T
	C1	CARLSON et al., Perineurium in the Drosophila embryo and its role in the blood-brain/nerve barrier, 1998, Int. J. Insect Morphology and Embryology 27(2):61-66	
	C2	BANKS et al., Delivery across the blood-brain barrier of antisense directed against Amyloid beta: reversal of learning and memory deficits in mice overexpressing Amyloid precursor protein, 2001, J. Pharmacology and Experimental Therapeutics 297(3):1113-1121	
	C3	PARDRIDGE et al., Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier in vivo, 1995, Proc. Nat. Acad. Sci. USA 92:5592-5596	
	C4	BOADO et al., Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS, 1998, J. Pharm. Sci. 87(11):1308-1315	
	C5	TYLER et al., Peptide nucleic acids targeted to the neurotensin receptor and administered i.p. cross the blood-brain barrier and specifically reduce gene expression, 1999, Proc. Natl. Acad. Sci. USA 96:7053-7058	
	C6	LEE et al., Imaging gene expression in the brain in vivo in a transgenic mouse model of Huntington's disease with an antisense radiopharmaceutical and drug-targeting technology, 2002, J. Nuclear Medicine 43(7):948-956	
	C7	PENICHERT et al., An antibody-Avidin fusion protein specific for the Transferrin Receptor serves as a delivery vehicle for the effective brain targeting: initial applications in anti-HIV antisense drug delivery to the brain, 1999, J. Immun. 163:4421-4426	
	C8	WU et al., Pharmacokinetics and blood-brain barrier transport of [3H]-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system, 1996, J. Pharm. Exp. Ther. and Am. Soc. Pharm. 276(1):206-211	
Examiner Signature		Date Considered	

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



PATENT

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Substitute for form 1449/PTO				Complete if Known	
<p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p>				Application Number	10/511,657
				Filing Date	April 18, 2005
				First Named Inventor	Drumm
				Group Art Unit	1635
				Examiner Name	Wollenberger, Louis V
Sheet	2	of	2	Attorney Docket Number	129402.00201
/L.W./	C9	SHI et al., Antisense imaging of gene expression in the brain in vivo, 2000, Proc. Natl. Acad. Sci. USA 97(26):14709-14714			
	C10	BOADO, Antisense drug delivery through the blood-brain barrier, 1995, Adv. Drug Delivery Reviews 15(1/3):73-107			
	C11	PINEDA et al., The genetic network of prototypic planarian eye regeneration is Pax6 independent, 2002, Development 129:1423-1434			
	C12	DRYJA et al., Mutations in the gene encoding the alpha subunit of the rod cGMP-gated channel in autosomal recessive retinitis pigmentosa, 1995, Proc. Natl. Acad. Sci. USA 92:10177-10181			
	C13	HUNT et al., Vitreous treatment of retinal pigment epithelial cells results in decreased expression of FGF-2, 1998, Investigative Ophthalmology & Visual Sci. 39(11):2111-2120			
	C14	KOCIOK et al., Vitreous treatment of cultured human RPE cells results in differential expression of 10 new genes, 2002, Investigative Ophthalmology & Visual Sci. 43(7):2474-2480			
	C15	CAMPOCHIARO, Gene therapy for retinal and choroidal diseases, 2002, Expert Opinion on Biological Therapy, 2(5):537-544			
	C16	KOCIOK et al., Upregulation of RAS-GTPase Activating Protein (GAP)-Binding Protein (G388P) in proliferating RPE cells, 1999, J. Cellular Biochemistry 74:194-201			
	C17	CHAN et al., Expression of chemokine receptors, CXCR4 and CXCR5, and chemokines, BLC and SDF-1, in the eyes of patients with primary intraocular lymphoma, 2003, Ophthalmology 110(2):421-426			
	C18	AVGEROPOULOS et al., New treatment strategies for malignant gliomas, 1999, The Oncologist 4:209-224			
	C19	GROOTHUIS, The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery, 2000, Neuro-Oncology 2:45-59			
	C20	PARDRIDGE, Brain drug targeting and gene technologies, 2001, Japanese J. Pharmacology 87:97-103			
	C21	PARDRIDGE, Drug and gene targeting to the brain with molecular Trojan horses, 2002, Nature Reviews 1:131-139			
	C22	QIAN et al., Targeted drug delivery via the Transferrin Receptor mediated endocytosis pathway, 2002, Pharmacological Reviews 54(4):561-587			
	C23	PARDRIDGE, Vector-Mediated drug delivery to the brain, 1999, Advanced Drug Delivery Reviews, 36(2-3):299-321			
	C24	PARDRIDGE, CNS drug design based on principles of blood-brain barrier transport, 1998, J. Neurochemistry 70:1781-1792			
	C25	PARDRIDGE, Drug delivery to the brain, 1997, J. Cerebral Blood Flow and Metabolism, 17(7):713-731			
	C26	PHILIP et al., Polarized expression of monocarboxylate transporters in human retinal pigment epithelium and ARPE-19 cells, 2003, Investigative Ophthalmology & Visual Sci. 44(4):1716-1721			
Examiner Signature	/Louis Wollenberger/			Date Considered	01/14/2008

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.